Qualifying for Wegovy insurance coverage means clearing two separate bars: the FDA's clinical criteria for who the drug is approved to treat, and your specific health plan's rules for who it agrees to pay for. Meeting the first doesn't guarantee the second, and that gap is where most denials happen in 2026.
TL;DR
- Wegovy requires a BMI of 30 or higher, or 27+ with a weight-related condition like hypertension.
- Most commercial plans require prior authorization even when you meet the BMI threshold.
- Employer plan design, not the FDA label, is the biggest reason coverage gets denied in 2026.
- STEP-1 trial data shows roughly 15% average weight loss on semaglutide; individual results vary.
- GoodLife Health's Cardiometabolic Optimization Membership works whether or not your plan covers the drug.
- Wegovy qualifies at a BMI of 30+, or 27-29.9 paired with a weight-related condition.
- Prior authorization is standard on most commercial plans, even when BMI criteria are met.
- Employer plan design, not the FDA label, is the biggest driver of coverage denials.
- STEP-1 trial data shows roughly 15% average weight loss on semaglutide.
- Medicare Part D covers Wegovy only for cardiovascular risk reduction, not general weight loss.
- Appeals succeed more often with new lab documentation than a repeat submission.
Why this matters
Insurance coverage for GLP-1 weight-loss drugs is inconsistent across plans in a way that coverage for, say, blood pressure medication isn't. A patient with a BMI of 32 can get approved at one employer and denied at the next, because the plan sponsor chose to exclude anti-obesity medications from the formulary entirely. That's a business decision, not a medical one, and it's the single biggest variable most patients never see coming.
GoodLife Health treats this as part of the clinical picture, not a side issue. A Cardiometabolic Optimization Membership built around quarterly Biomarker Audits gives your clinician the lab documentation - HbA1c, lipid panel, blood pressure readings - that a prior authorization reviewer actually wants to see, whether your plan ends up covering the prescription or not.
How to qualify for Wegovy through insurance
The path is procedural, not mysterious. Here's the sequence that determines whether a claim gets approved:
- Confirm your BMI meets the FDA threshold. That's 30 or higher on its own, or 27 to 29.9 paired with a qualifying condition.
- Document a weight-related condition if your BMI falls in the 27-29.9 range. Hypertension, type 2 diabetes, dyslipidemia, and sleep apnea are the conditions insurers most commonly accept.
- Check your plan's specific formulary tier and prior authorization rules. Wegovy sits on a specialty tier for most commercial plans, which almost always triggers a PA requirement.
- Have your prescriber submit clinical documentation. This typically includes BMI history, comorbidity-supporting labs, and any prior weight-management attempts.
- Complete step therapy if your plan requires it. Some insurers want documented attempts with a lower-tier medication or a structured diet program before approving Wegovy.
- Appeal a denial with additional lab documentation rather than resubmitting the same paperwork. A second submission with updated biomarkers changes outcomes more often than a repeat request.
BMI 30 and above: qualifies without a comorbidity
A BMI of 30 or higher meets the FDA's obesity threshold on its own, no additional diagnosis required. This is the cleanest qualification path and the one least likely to get bounced on medical necessity grounds, though prior authorization is still standard procedure even at this BMI level in 2026.
BMI 27 to 29.9: qualifies only with a weight-related condition
A BMI between 27 and 29.9 only meets the FDA label when paired with a documented weight-related condition - hypertension, type 2 diabetes, high cholesterol, or obstructive sleep apnea are the ones insurers recognize most consistently. Without that second diagnosis on the chart, a plan can deny the claim even though the prescriber wrote it correctly, which is why lab-backed documentation matters more at this BMI range than at 30-plus.
BMI Qualification Paths
| BMI Range | Additional Requirement | Conditions Accepted |
|---|---|---|
| 30 or higher | None required | Not applicable |
| 27 to 29.9 | Documented weight-related condition | Hypertension, type 2 diabetes, high cholesterol, obstructive sleep apnea |
Why Wegovy coverage varies so much
The FDA label is the same for every patient. What changes is the plan design sitting on top of it.
- Employer plan choices - many self-funded employer plans opt out of anti-obesity drug coverage entirely, regardless of medical necessity.
- State insurance mandates - a small number of states require some level of anti-obesity medication coverage; most don't.
- Formulary tier placement - specialty-tier placement usually means mandatory prior authorization and sometimes a higher patient cost share.
- Step therapy requirements - some plans want documented failure with a cheaper agent or a structured lifestyle program first.
- Diagnosis code on the claim - a claim coded for obesity treatment gets reviewed differently than one coded for a cardiovascular risk indication.
- Reauthorization checkpoints - several plans require documented weight loss progress at 3 or 6 months to continue coverage, not just an initial approval.
Several plans require documented weight loss progress at 3 or 6 months to continue coverage, not just an initial approval. A flat-fee model built around quarterly biomarker tracking gives your clinician the documentation trail these checkpoints require, instead of scrambling for lab values right before a reauthorization deadline.
A flat-fee model built around quarterly biomarker tracking gives your clinician the documentation trail these checkpoints require, instead of scrambling for lab values right before a reauthorization deadline.
Does Medicare cover Wegovy?
Medicare Part D began covering Wegovy for a narrower indication in 2024, after the FDA expanded the drug's label to include reducing cardiovascular risk - heart attack, stroke, cardiovascular death - in adults with established cardiovascular disease and obesity or overweight. That expansion came out of the SELECT cardiovascular outcomes trial, and it's a different qualifying pathway than straightforward weight-loss coverage, which Medicare still generally excludes.
Is Ozempic easier to get approved than Wegovy?
Ozempic is FDA-approved for type 2 diabetes, and insurers cover diabetes medications far more readily than obesity medications, even though Ozempic and Wegovy share the same active ingredient, semaglutide. A patient without a type 2 diabetes diagnosis generally can't get Ozempic approved for weight loss under that indication, which is why Wegovy exists as the separate, obesity-labeled version of the same molecule.
What happens if your prior authorization is denied?
A prior authorization denial is not a final answer - most plans allow at least one formal appeal, and appeals succeed more often when the resubmission includes new documentation rather than repeating the original paperwork. Updated labs showing an A1c trend, a blood pressure reading, or a lipid panel change in the wrong direction give a reviewer a new reason to approve the claim on the second pass.
That's a business decision, not a medical one, and it's the single biggest variable most patients never see coming.
FAQ
What BMI do you need to qualify for Wegovy insurance coverage?
A BMI of 30 or higher qualifies on its own under the FDA label. A BMI of 27 to 29.9 only qualifies when paired with a documented weight-related condition like hypertension or type 2 diabetes.
Does insurance require prior authorization for Wegovy?
Most commercial plans require prior authorization for Wegovy because it sits on a specialty formulary tier. Approval typically depends on documented BMI and, where applicable, a qualifying comorbidity.
Can you get Wegovy covered without diabetes?
Yes, Wegovy is FDA-approved for chronic weight management independent of a diabetes diagnosis, unlike Ozempic which is labeled for type 2 diabetes. Coverage still depends on your plan's specific formulary rules.
Does Medicare cover Wegovy?
Medicare Part D began covering Wegovy in 2024 for a narrower cardiovascular risk-reduction indication in patients with established heart disease, following the SELECT trial. Straightforward weight-loss coverage is still generally excluded.
What happens if insurance denies Wegovy?
A denial usually isn't final - most plans allow a formal appeal, and appeals succeed more often with new lab documentation rather than a repeat of the original submission.
Is Ozempic easier to get approved than Wegovy?
Ozempic is often easier to get covered because it's approved for type 2 diabetes, a category insurers cover more consistently than obesity treatment, even though both drugs use semaglutide.
Does GoodLife Health bill insurance for Wegovy?
GoodLife Health's membership fee is flat and separate from the medication. Wegovy itself is billed by the pharmacy at pharmacy cost, whether that runs through your insurance or not, with no markup added by GoodLife Health.
How long does prior authorization for Wegovy take?
Timelines vary by plan, but most commercial insurers process a standard prior authorization request within one to two weeks once complete clinical documentation is submitted.
One last thing
The FDA's 2024 label expansion for Wegovy - covering cardiovascular risk reduction in patients with established heart disease - changed more than the drug's marketing. It opened a second diagnosis pathway that some plans review differently than a straight obesity claim, and patients with a cardiovascular history who've been denied under a weight-loss code sometimes get approved when the same prescription is documented against that cardiovascular indication instead. It's worth asking your clinician which code was used on your original submission before you assume the door is closed.
Related guides
- How to get Wegovy prescribed for weight loss
- Wegovy cost without insurance: what patients pay
- How prior authorization works for Zepbound coverage
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/